Structure Based Prediction of Asparagine Deamidation Propensity in Monoclonal Antibodies

References

• Haberger M, Bomans K, Diepold K, Hook M, Gassner J, Schlothauer T, Zwick A, Spick C, Kepert JF, Hienz B, et al. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: susceptibility vs. functionality of critical quality attributes. MAbs. 2014;6:327–339. doi:10.4161/mabs.27876.
   PubMed Web of Science ®Google Scholar
• Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem. 2005;77:1432–1439. doi:10.1021/ac0494174.
   PubMed Web of Science ®Google Scholar
• Yan B, Steen S, Hambly D, Valliere-Douglass J, Vanden Bos T, Smallwood S, Yates Z, Arroll T, Han Y, Gadgil H, et al. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci. 2009;98:3509–3521. doi:10.1002/jps.21655.
   PubMed Web of Science ®Google Scholar
• Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl. 752;2001:233–245.
   PubMed Web of Science ®Google Scholar
• Bumbaca Yadav D, Sharma VK, Boswell CA, Hotzel I, Tesar D, Shang Y, Ying Y, Fischer SK, Grogan JL, Chiang EY, et al. Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics. J Biol Chem. 2015;290:29732–29741. doi:10.1074/jbc.M115.692434.
   PubMed Web of Science ®Google Scholar
• Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci USA. 2015;112:5997–6002. doi:10.1073/pnas.1408766112.
   PubMed Web of Science ®Google Scholar
• Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 262;1987:785–794.
   PubMed Web of Science ®Google Scholar
• Stephenson RC, Clarke S. Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins. J Biol Chem. 264;1989:6164–6170.
   PubMed Web of Science ®Google Scholar
• Xie M, Schowen RL. Secondary structure and protein deamidation. J Pharm Sci. 1999;88:8–13. doi:10.1021/js9802493.
   PubMed Web of Science ®Google Scholar
• Chu GC, Chelius D, Xiao G, Khor HK, Coulibaly S, Bondarenko PV. Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures. Pharm Res. 2007;24:1145–1156. doi:10.1007/s11095-007-9241-4.
   PubMed Web of Science ®Google Scholar
• Robinson NE, Robinson AB. Prediction of primary structure deamidation rates of asparaginyl and glutaminyl peptides through steric and catalytic effects. J Pept Res. 2004;63:437–448. doi:10.1111/j.1399-3011.2004.00148.x.
   PubMedGoogle Scholar
• Robinson NE, Robinson AB. Molecular clocks. Proc Natl Acad Sci USA. 2001;98:944–949. doi:10.1073/pnas.98.3.944.
   PubMed Web of Science ®Google Scholar
• Xie M, Shahrokh Z, Kadkhodayan M, Henzel WJ, Powell MF, Borchardt RT, Schowen RL. Asparagine deamidation in recombinant human lymphotoxin: hindrance by three-dimensional structures. J Pharm Sci. 2003;92:869–880. doi:10.1002/jps.10342.
   PubMed Web of Science ®Google Scholar
• Kosky AA, Razzaq UO, Treuheit MJ, Brems DN. The effects of alpha-helix on the stability of Asn residues: deamidation rates in peptides of varying helicity. Protein Sci. 1999;8:2519–2523. doi:10.1110/ps.8.11.2519.
   PubMed Web of Science ®Google Scholar
• Robinson NE, Robinson AB. Prediction of protein deamidation rates from primary and three-dimensional structure. Proc Natl Acad Sci USA. 2001;98:4367–4372. doi:10.1073/pnas.071066498.
   PubMed Web of Science ®Google Scholar
• Sydow JF, Lipsmeier F, Larraillet V, Hilger M, Mautz B, Molhoj M, Kuentzer J, Klostermann S, Schoch J, Voelger HR, et al. Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions. PLoS One. 2014;9:e100736. doi:10.1371/journal.pone.0100736.
   PubMed Web of Science ®Google Scholar
• Capasso S. Estimation of the deamidation rate of asparagine side chains. J Pept Res. 55;2000:224–229.
   PubMedGoogle Scholar
• Peters B, Trout BL. Asparagine deamidation: pH-dependent mechanism from density functional theory. Biochemistry. 2006;45:5384–5392. doi:10.1021/bi052438n.
   PubMed Web of Science ®Google Scholar
• Chelius D, Rehder DS, Bondarenko PV. Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. Anal Chem. 2005;77:6004–6011. doi:10.1021/ac050672d.
   PubMed Web of Science ®Google Scholar
• Zhang YT, Hu J, Pace AL, Wong R, Wang YJ, Kao YH. Characterization of asparagine 330 deamidation in an Fc-fragment of IgG1 using cation exchange chromatography and peptide mapping. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;965:65–71. doi:10.1016/j.jchromb.2014.06.018.
   PubMed Web of Science ®Google Scholar
• Davies AM, Sutton BJ. Human IgG4: a structural perspective. Immunol Rev. 2015;268:139–159. doi:10.1111/imr.12349.
   PubMed Web of Science ®Google Scholar
• Neergaard MS, Nielsen AD, Parshad H, Van De Weert M. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass. J Pharm Sci. 2014;103:115–127. doi:10.1002/jps.23788.
   PubMed Web of Science ®Google Scholar
• Liang S, Dai J, Hou S, Su L, Zhang D, Guo H, Hu S, Wang H, Rao Z, Guo Y, et al. Structural basis for treating tumor necrosis factor alpha (TNFalpha)-associated diseases with the therapeutic antibody infliximab. J Biol Chem. 2013;288:13799–13807. doi:10.1074/jbc.M112.433961.
   PubMed Web of Science ®Google Scholar